Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our Best Content in Your Email

You are already a member! Please enter your password to sign in.

IGC’s Cannabis-Formulation for Alzheimer's to Become Available in Early 2018

Featured Submission, Featured Submission
0 Comments| December 5, 2017


India Globalization Capital Inc. (NYSE American: IGC) expects to make its proprietary liquid cannabis-based formulation, named Hyalolex, for Alzheimer’s, available through medical cannabis dispensaries in early 2018.  Based on in vitro, in vivo, and clinical studies, including data collected by the University of South Florida, Hyalolex may help Alzheimer’s patients control several end points of the devastating disease including symptoms like anxiety, agitation, and sleep disorder, among others.  In the United States, the use of cannabis for medical purposes is legal in 29 states and IGC is currently in the process of initiating pilot programs in Washington, D.C., Maryland, Pennsylvania, and California.  Internationally, the Company expects to commercialize the product in Canada and Germany.  Independent of these launches and subject to financing, IGC plans to take the formulation through the FDA process to qualify it as a pharmaceutical drug.

Alzheimer's, the most common cause of dementia among older adults, is a chronic neurodegenerative disease that progressively destroys memory and cognitive skills.  Alzheimer's affects 44 million people worldwide and around 6 million in the U.S. and Canada, according to the Alzheimer's Association.  The cost associated with Alzheimer’s is projected to exceed $1 trillion by 2025.

Currently there is no acceptable cure for Alzheimer’s Disease and securing a viable treatment option is considered the Holy Grail by pharmaceutical companies seeking to make a difference in the lives of so many.  Even Bill Gates has become active publicly and recently made a substantial investment to fund nontraditional approaches to conquer the devastating disease.

Even before symptoms like loss of memory manifest, two key markers for the disease, among others, are present and identifiable in the brain.  The first marker is the presence of extracellular plaque composed of amyloid beta peptides (Aβ plaque).  The second key marker is intracellular neuro fibrillary tangles (NFTs). It has been shown that Aβ peptide monomers aggregate into Aβ oligomers and deposit as plaque, and hyperphosphorylation of tau protein by glycogen synthase kinase-3β (GSK3β) leads to tangles.

IGC recently acquired exclusive rights to a novel cannabis-based combination therapy for Alzheimer's from the University of South Florida (USF).  The lead investigator at the university discovered that cannabis extracts in combination with other molecules, in vitro, decrease the aggregation of Aβ by as much as 40%, and decrease the expression of GSK3β by as much as 62%, thus reducing the propensity to form both plaque and tangles.  Further, this is achieved without the side effects commonly associated with cannabis.

Under the definitive license agreement with the University of South Florida, IGC is the exclusive licensee of the patent filing 'THC as a Potential Therapeutic Agent for Alzheimer's Disease,' which claims the discovery of a new pathway in which low doses of Tetrahydrocannabinol (THC) in combination with other molecules inhibit the buildup of plaques and tangles.  This new pathway offers exciting potential in the treatment of Alzheimer's.  The patent filing also helps IGC protect its proprietary formulation of Hyalolex.  The lead investigator at the University of South Florida, an Advisor to IGC, was featured on CNN by Dr. Sanjay Gupta on the 'Weed 3, The Marijuana Revolution,' available for viewing at www://igcpharma.com

In addition to Hyalolex, the company's other cannabis-based product portfolio is shown in the chart below.  It includes Natrinol for the treatment of cachexia in AIDS and cancer patients; Serosapse, which addresses various Parkinson's disease endpoints; and Caesafin, which employs combination therapy to alleviate seizures in dogs and cats.

IndiaSTS_1-(4).png
(click to enlarge)

Cannabis pharmaceutical companies in the peer group currently have market capitalizations ranging from $70 million up to $500 million as compared to IGC's $15 million.  Progress by IGC on multiple fronts, including its unique Alzheimer’s formulation, and increased investor awareness, could afford IGC a valuation similar to its peers providing investors with a timely opportunity to take a closer look at the Company.  

For more information on the Company, please visit: www.igcpharma.com
For more information on Hyalolex, please visit: http://hyalolex.com/

Forward-looking Statements:

Please see forward-looking statements and risk factors as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Social media:

https://www.facebook.com/IGCIR/
https://twitter.com/IGCIR
https://www.linkedin.com/company/15401411/




FULL DISCLOSURE: India Globalization Capital Inc. is a paid client of Stockhouse Publishing.

Tags:

Rate this article
0 stars
v
Usefulness

Clarity

Credibility

Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Healthcare

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.